{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:15:48Z","timestamp":1794960948088,"version":"4.9.1"},"reference-count":144,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Biomarkers are increasingly recognized to have significant clinical value in early identification\nand progression of various cardiovascular diseases. There are many heart conditions, such\nas congestive heart failure (CHF), ischemic heart diseases (IHD), and diabetic cardiomyopathy (DCM),\nand cardiac remodeling, in which the severity of the cardiac pathology can be mirrored\nthrough these cardiac biomarkers. From the emergency department (ED) evaluation of acute coronary\nsyndromes (ACS) or suspected acute myocardial infarction (AMI) with cardiac marker Troponin\nto the diagnosis of chronic conditions like Heart Failure (HF) with natriuretic peptides, like\nB-type natriuretic peptide (BNP), N-terminal pro-B- type natriuretic peptide (Nt-proBNP) and mid\nregional pro-atrial natriuretic peptide (MR- proANP), their use is continuously increasing. Their\nclinical importance has led to the discovery of newer biomarkers, such as the soluble source of tumorigenicity\n2 (sST2), galectin-3 (Gal-3), growth differentiation factor-15 (GDF-15), and various\nmicro ribonucleic acids (miRNAs). Since cardiac pathophysiology involves a complex interplay between\ninflammatory, genetic, neurohormonal, and biochemical levels, these biomarkers could be\nenzymes, hormones, and biologic substances showing cardiac injury, stress, and malfunction.\nTherefore, multi-marker approaches with different combinations of novel cardiac biomarkers, and\ncontinual assessment of cardiac biomarkers are likely to improve cardiac risk prediction, stratification,\nand overall patient wellbeing. On the other hand, these biomarkers may reflect coexisting or\nisolated disease processes in different organ systems other than the cardiovascular system. Therefore,\nknowledge of cardiac biomarkers is imperative. In this article, we have reviewed the role of\ncardiac biomarkers and their use in the diagnosis and prognosis of various cardiovascular diseases\nfrom different investigations conducted in recent years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871530320999200831171748","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T04:25:37Z","timestamp":1598934337000},"page":"980-993","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Current Use of Cardiac Biomarkers in Various Heart Conditions"],"prefix":"10.2174","volume":"21","author":[{"given":"Shahzad","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan 4300711,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahibzada T.","family":"Rasool","sequence":"additional","affiliation":[{"name":"King Faisal University, Al-Ahsa,Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski P.","year":"2016","unstructured":"Ponikowski P.; Voors A.A.; Anker S.D.; Bueno H.; Cleland J.G.; Coats A.J.; Falk V.; Gonz\u00e1lez-Juanatey J.R.; Harjola V.P.; Jankowska E.A.; Jessup M.; Linde C.; Nihoyannopoulos P.; Parissis J.T.; Pieske B.; Riley J.P.; Rosano G.M.; Ruilope L.M.; Ruschitzka F.; Rutten F.H.; van der Meer P.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016,18(8),891-975","journal-title":"Eur J Heart Fail"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"Owan T.E.","year":"2006","unstructured":"Owan T.E.; Hodge D.O.; Herges R.M.; Jacobsen S.J.; Roger V.L.; Redfield M.M.; Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006,355(3),251-259","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/joim.12756","volume":"283","author":"Magnussen C.","year":"2018","unstructured":"Magnussen C.; Blankenberg S.; Biomarkers for heart failure: small molecules with high clinical relevance. J Intern Med 2018,283(6),530-543","journal-title":"J Intern Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","year":"2001","unstructured":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001,69(3),89-95","journal-title":"Clin Pharmacol Ther"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/01.CIR.90.1.195","volume":"90","author":"Yasue H.","year":"1994","unstructured":"Yasue H.; Yoshimura M.; Sumida H.; Kikuta K.; Kugiyama K.; Jougasaki M.; Ogawa H.; Okumura K.; Mukoyama M.; Nakao K.; Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994,90(1),195-203","journal-title":"Circulation"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jacc.2005.11.030","volume":"47","author":"Iwanaga Y.","year":"2006","unstructured":"Iwanaga Y.; Nishi I.; Furuichi S.; Noguchi T.; Sase K.; Kihara Y.; Goto Y.; Nonogi H.; B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006,47(4),742-748","journal-title":"J Am Coll Cardiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMoa031994","volume":"350","author":"Wang T.J.","year":"2004","unstructured":"Wang T.J.; Larson M.G.; Levy D.; Benjamin E.J.; Leip E.P.; Omland T.; Wolf P.A.; Vasan R.S.; Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004,350(7),655-663","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ejheart.2008.07.014","volume":"10","author":"Maisel A.","year":"2008","unstructured":"Maisel A.; Mueller C.; Adams K.; Anker S.D.; Aspromonte N.; Cleland J.G.; Cohen-Solal A.; Dahlstrom U.; DeMaria A.; Di Somma S.; Filippatos G.S.; Fonarow G.C.; Jourdain P.; Komajda M.; Liu P.P.; McDonagh T.; McDonald K.; Mebazaa A.; Nieminen M.S.; Peacock W.F.; Tubaro M.; Valle R.; Vanderhyden M.; Yancy C.W.; Zannad F.; Braunwald E.; State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008,10(9),824-839","journal-title":"Eur J Heart Fail"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMoa020233","volume":"347","author":"Maisel A.S.","year":"2002","unstructured":"Maisel A.S.; Krishnaswamy P.; Nowak R.M.; McCord J.; Hollander J.E.; Duc P.; Omland T.; Storrow A.B.; Abraham W.T.; Wu A.H.; Clopton P.; Steg P.G.; Westheim A.; Knudsen C.W.; Perez A.; Kazanegra R.; Herrmann H.C.; McCullough P.A.; Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002,347(3),161-167","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","volume":"135","author":"Chow S.L.","year":"2017","unstructured":"Chow S.L.; Maisel A.S.; Anand I.; Bozkurt B.; de Boer R.A.; Felker G.M.; Fonarow G.C.; Greenberg B.; Januzzi J.L.; Kiernan M.S.; Liu P.P.; Wang T.J.; Yancy C.W.; Zile M.R.; Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2017,135(22),e1054-e1091","journal-title":"Circulation"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000313528","volume":"56","author":"Nellessen U.","year":"2010","unstructured":"Nellessen U.; Zingel M.; Hecker H.; Bahnsen J.; Borschke D.; Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? Chemotherapy 2010,56(2),147-152","journal-title":"Chemotherapy"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/chf.12016","volume":"19","author":"Gaggin H.K.","year":"2013","unstructured":"Gaggin H.K.; Truong Q.A.; Rehman S.U.; Mohammed A.A.; Bhardwaj A.; Parks K.A.; Sullivan D.A.; Chen-Tournoux A.; Moore S.A.; Richards A.M.; Troughton R.W.; Lainchbury J.G.; Weiner R.B.; Baggish A.L.; Semigran M.J.; Januzzi J.L.; Characterization and prediction of natriuretic peptide \u201cnonresponse\u201d during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail 2013,19(3),135-142","journal-title":"Congest Heart Fail"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jacc.2007.02.037","volume":"49","author":"Fonarow G.C.","year":"2007","unstructured":"Fonarow G.C.; Peacock W.F.; Phillips C.O.; Givertz M.M.; Lopatin M.; Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007,49(19),1943-1950","journal-title":"J Am Coll Cardiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0735-1097(00)01157-8","volume":"37","author":"Cheng V.","year":"2001","unstructured":"Cheng V.; Kazanagra R.; Garcia A.; Lenert L.; Krishnaswamy P.; Gardetto N.; Clopton P.; Maisel A.; A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001,37(2),386-391","journal-title":"J Am Coll Cardiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1388-9842(03)00098-9","volume":"5","author":"O\u2019Brien R.J.","year":"2003","unstructured":"O\u2019Brien R.J.; Squire I.B.; Demme B.; Davies J.E.; Ng L.L.; Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003,5(4),499-506","journal-title":"Eur J Heart Fail"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0140-6736(03)13976-1","volume":"362","author":"de Lemos J.A.","year":"2003","unstructured":"de Lemos J.A.; McGuire D.K.; Drazner M.H.; B-type natriuretic peptide in cardiovascular disease. Lancet 2003,362(9380),316-322","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","volume":"110","author":"Bettencourt P.","year":"2004","unstructured":"Bettencourt P.; Azevedo A.; Pimenta J.; Fri\u00f5es F.; Ferreira S.; Ferreira A.; N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004,110(15),2168-2174","journal-title":"Circulation"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/bmj.330.7492.625","volume":"330","author":"Doust J.A.","year":"2005","unstructured":"Doust J.A.; Pietrzak E.; Dobson A.; Glasziou P.; How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005,330(7492),625","journal-title":"BMJ"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1373\/clinchem.2011.165720","volume":"58","author":"van Kimmenade R.R.","year":"2012","unstructured":"van Kimmenade R.R.; Januzzi J.L.; Emerging biomarkers in heart failure. Clin Chem 2012,58(1),127-138","journal-title":"Clin Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1016\/j.ijcard.2013.04.164","volume":"168","author":"Seronde M.F.","year":"2013","unstructured":"Seronde M.F.; Gayat E.; Logeart D.; Lassus J.; Laribi S.; Boukef R.; Sibellas F.; Launay J.M.; Manivet P.; Sadoune M.; Nouira S.; Solal A.C.; Mebazaa A.; Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol 2013,168(4),3404-3411","journal-title":"Int J Cardiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1161\/CIRCULATIONAHA.111.044149","volume":"125","author":"Masson S.","year":"2012","unstructured":"Masson S.; Anand I.; Favero C.; Barlera S.; Vago T.; Bertocchi F.; Maggioni A.P.; Tavazzi L.; Tognoni G.; Cohn J.N.; Latini R.; Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 2012,125(2),280-288","journal-title":"Circulation"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ahj.2013.02.008","volume":"165","author":"Gravning J.","year":"2013","unstructured":"Gravning J.; Smedsrud M.K.; Omland T.; Eek C.; Skulstad H.; Aaberge L.; Bendz B.; Kjekshus J.; M\u00f8rkrid L.; Edvardsen T.; Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Am Heart J 2013,165(5),716-724","journal-title":"Am Heart J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamacardio.2016.0695","volume":"1","author":"Neumann J.T.","year":"2016","unstructured":"Neumann J.T.; S\u00f6rensen N.A.; Schwemer T.; Ojeda F.; Bourry R.; Sciacca V.; Schaefer S.; Waldeyer C.; Sinning C.; Renn\u00e9 T.; Than M.; Parsonage W.; Wildi K.; Makarova N.; Schnabel R.B.; Landmesser U.; Mueller C.; Cullen L.; Greenslade J.; Zeller T.; Blankenberg S.; Karakas M.; Westermann D.; Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. JAMA Cardiol 2016,1(4),397-404","journal-title":"JAMA Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1415921","volume":"373","author":"Everett B.M.","year":"2015","unstructured":"Everett B.M.; Brooks M.M.; Vlachos H.E.; Chaitman B.R.; Frye R.L.; Bhatt D.L.; Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med 2015,373(7),610-620","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","volume":"128","author":"Yancy C.W.","year":"2013","unstructured":"Yancy C.W.; Jessup M.; Bozkurt B.; Butler J.; Casey D.E.; Drazner M.H.; Fonarow G.C.; Geraci S.A.; Horwich T.; Januzzi J.L.; Johnson M.R.; Kasper E.K.; Levy W.C.; Masoudi F.A.; McBride P.E.; McMurray J.J.; Mitchell J.E.; Peterson P.N.; Riegel B.; Sam F.; Stevenson L.W.; Tang W.H.W.; Tsai E.J.; Wilkoff B.L.; 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 2013,128(16),e240-e327","journal-title":"Circulation"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1373\/clinchem.2016.261495","volume":"63","author":"Eggers K.M.","year":"2017","unstructured":"Eggers K.M.; Lindahl B.; Application of cardiac troponin in cardiovascular diseases other than acute coronary syndrome. Clin Chem 2017,63(1),223-235","journal-title":"Clin Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"Thygesen K.","year":"2018","unstructured":"Thygesen K.; Alpert J.S.; Jaffe A.S.; Chaitman B.R.; Bax J.J.; Morrow D.A.; White H.D.; Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018,72(18),2231-2264","journal-title":"J Am Coll Cardiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1016\/j.jacc.2018.04.029","volume":"71","author":"Weil B.R.","year":"2018","unstructured":"Weil B.R.; Suzuki G.; Young R.F.; Iyer V.; Canty J.M.; Troponin Release and Reversible Left\u00a0Ventricular Dysfunction After Transient Pressure\u00a0Overload. J Am Coll Cardiol 2018,71(25),2906-2916","journal-title":"J Am Coll Cardiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11897-019-0420-5","volume":"16","author":"Harrison N.","year":"2019","unstructured":"Harrison N.; Favot M.; Levy P.; The Role of Troponin for Acute Heart Failure. Curr Heart Fail Rep 2019,16(1),21-31","journal-title":"Curr Heart Fail Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0022-2828(84)80609-4","volume":"16","author":"Piper H.M.","year":"1984","unstructured":"Piper H.M.; Schwartz P.; Spahr R.; H\u00fctter J.F.; Spieckermann P.G.; Early enzyme release from myocardial cells is not due to irreversible cell damage. J Mol Cell Cardiol 1984,16(4),385-388","journal-title":"J Mol Cell Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.jacc.2012.08.969","volume":"60","author":"Newby L.K.","year":"2012","unstructured":"Newby L.K.; Jesse R.L.; Babb J.D.; Christenson R.H.; De Fer T.M.; Diamond G.A.; Fesmire F.M.; Geraci S.A.; Gersh B.J.; Larsen G.C.; Kaul S.; McKay C.R.; Philippides G.J.; Weintraub W.S.; ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2012,60(23),2427-2463","journal-title":"J Am Coll Cardiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"i","DOI":"10.3310\/hta18660","volume":"18","author":"Scott D.L.","year":"2014","unstructured":"Scott D.L.; Ibrahim F.; Farewell V.; O\u2019Keeffe A.G.; Ma M.; Walker D.; Heslin M.; Patel A.; Kingsley G.; Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. Health Technol Assess 2014,18(66),i-xxiv, 1-164","journal-title":"Health Technol Assess"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cca.2019.04.061","volume":"495","author":"Clemens R.K.","year":"2019","unstructured":"Clemens R.K.; Annema W.; Baumann F.; Roth-Zetzsche S.; Seifert B.; von Eckardstein A.; Amann-Vesti B.R.; Cardiac biomarkers but not measures of vascular atherosclerosis predict mortality in patients with peripheral artery disease. Clin Chim Acta 2019,495,215-220","journal-title":"Clin Chim Acta"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.athoracsur.2019.04.123","volume":"108","author":"Ramkumar N.","year":"2019","unstructured":"Ramkumar N.; Jacobs J.P.; Berman R.B.; Parker D.M.; MacKenzie T.A.; Likosky D.S.; DiScipio A.; Malenka D.J.; Brown J.R.; Cardiac biomarkers predict long-term survival after cardiac surgery. Ann Thorac Surg 2019,108(6),1776-1782","journal-title":"Ann Thorac Surg"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/heartjnl-2018-313145","volume":"105","author":"Niederd\u00f6ckl J.","year":"2019","unstructured":"Niederd\u00f6ckl J.; Simon A.; Schnaubelt S.; Schuetz N.; Laggner R.; Sulzgruber P.; Spiel A.O.; Herkner H.; Laggner A.N.; Domanovits H.; Cardiac biomarkers predict mortality in emergency patients presenting with atrial fibrillation. Heart 2019,105(6),482-488","journal-title":"Heart"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00392-018-1365-5","volume":"108","author":"Kreusser M.M.","year":"2019","unstructured":"Kreusser M.M.; Geis N.A.; Berlin N.; Greiner S.; Pleger S.T.; Bekeredjian R.; Katus H.A.; Raake P.W.; Invasive hemodynamics and cardiac biomarkers to predict outcomes after percutaneous edge-to-edge mitral valve repair in patients with severe heart failure. Clin Res Cardiol 2019,108(4),375-387","journal-title":"Clin Res Cardiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1056\/NEJMoa0805299","volume":"361","author":"Omland T.","year":"2009","unstructured":"Omland T.; de Lemos J.A.; Sabatine M.S.; Christophi C.A.; Rice M.M.; Jablonski K.A.; Tjora S.; Domanski M.J.; Gersh B.J.; Rouleau J.L.; Pfeffer M.A.; Braunwald E.; A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009,361(26),2538-2547","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","volume":"358","author":"Peacock W.F.","year":"2008","unstructured":"Peacock W.F.; De Marco T.; Fonarow G.C.; Diercks D.; Wynne J.; Apple F.S.; Wu A.H.; Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008,358(20),2117-2126","journal-title":"N Engl J Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1161\/01.CIR.103.3.369","volume":"103","author":"Sato Y.","year":"2001","unstructured":"Sato Y.; Yamada T.; Taniguchi R.; Nagai K.; Makiyama T.; Okada H.; Kataoka K.; Ito H.; Matsumori A.; Sasayama S.; Takatsu Y.; Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001,103(3),369-374","journal-title":"Circulation"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199610313351802","volume":"335","author":"Antman E.M.","year":"1996","unstructured":"Antman E.M.; Tanasijevic M.J.; Thompson B.; Schactman M.; McCabe C.H.; Cannon C.P.; Fischer G.A.; Fung A.Y.; Thompson C.; Wybenga D.; Braunwald E.; Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996,335(18),1342-1349","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0009-8981(95)06168-1","volume":"245","author":"Mair J.","year":"1996","unstructured":"Mair J.; Genser N.; Morandell D.; Maier J.; Mair P.; Lechleitner P.; Calzolari C.; Larue C.; Ambach E.; Dienstl F.; Pau B.; Puschendorf B.; Cardiac troponin I in the diagnosis of myocardial injury and infarction. Clin Chim Acta 1996,245(1),19-38","journal-title":"Clin Chim Acta"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/clinchem\/40.7.1291","volume":"40","author":"Adams J.E.","year":"1994","unstructured":"Adams J.E.; Schechtman K.B.; Landt Y.; Ladenson J.H.; Jaffe A.S.; Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994,40(7 Pt 1),1291-1295","journal-title":"Clin Chem"},{"key":"ref=43","first-page":"15130","volume":"10010","author":"Missov E.","year":"1997","unstructured":"Missov E.; Calzolari C.; Pau B.; In Increased levels of cardiac troponin I in cancer patients, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC 655 AVENUE OF THE AMERICAS. NEW YORK, NY 1997,10010,15130-15130","journal-title":"NEW YORK, NY"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/clinchem\/42.7.1120a","volume":"42","author":"L\u00f6fberg M.","year":"1996","unstructured":"L\u00f6fberg M.; T\u00e4htel\u00e4 R.; H\u00e4rk\u00f6nen M.; Somer H.; Cardiac troponins in severe rhabdomyolysis. Clin Chem 1996,42(7),1120-1121","journal-title":"Clin Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0002-9149(94)90845-1","volume":"74","author":"Lewis W.R.","year":"1994","unstructured":"Lewis W.R.; Amsterdam E.A.; Utility and safety of immediate exercise testing of low-risk patients admitted to the hospital for suspected acute myocardial infarction. Am J Cardiol 1994,74(10),987-990","journal-title":"Am J Cardiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0735-1097(96)00093-9","volume":"28","author":"Gomez M.A.","year":"1996","unstructured":"Gomez M.A.; Anderson J.L.; Karagounis L.A.; Muhlestein J.B.; Mooers F.B.; Group R.S.; An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO). J Am Coll Cardiol 1996,28(1),25-33","journal-title":"J Am Coll Cardiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","volume":"117","author":"Sanada S.","year":"2007","unstructured":"Sanada S.; Hakuno D.; Higgins L.J.; Schreiter E.R.; McKenzie A.N.; Lee R.T.; IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007,117(6),1538-1549","journal-title":"J Clin Invest"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrd2660","volume":"7","author":"Kakkar R.","year":"2008","unstructured":"Kakkar R.; Lee R.T.; The IL-33\/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008,7(10),827-840","journal-title":"Nat Rev Drug Discov"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bcp.2017.04.022","volume":"138","author":"Veeraveedu P.T.","year":"2017","unstructured":"Veeraveedu P.T.; Sanada S.; Okuda K.; Fu H.Y.; Matsuzaki T.; Araki R.; Yamato M.; Yasuda K.; Sakata Y.; Yoshimoto T.; Minamino T.; Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochem Pharmacol 2017,138,73-80","journal-title":"Biochem Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2009.08.047","volume":"55","author":"Weir R.A.","year":"2010","unstructured":"Weir R.A.; Miller A.M.; Murphy G.E.; Clements S.; Steedman T.; Connell J.M.; McInnes I.B.; Dargie H.J.; McMurray J.J.; Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010,55(3),243-250","journal-title":"J Am Coll Cardiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1112.e9","DOI":"10.1016\/j.amjmed.2017.02.034","volume":"130","author":"Jenkins W.S.","year":"2017","unstructured":"Jenkins W.S.; Roger V.L.; Jaffe A.S.; Weston S.A.; AbouEzzeddine O.F.; Jiang R.; Manemann S.M.; Enriquez-Sarano M.; Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. Am J Med 2017,130(9),1112.e9-1112.e15","journal-title":"Am J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"59B","DOI":"10.1016\/j.amjcard.2015.01.042","volume":"115","author":"deFilippi C.","year":"2015","unstructured":"deFilippi C.; Daniels L.B.; Bayes-Genis A.; Structural heart disease and ST2: cross-sectional and longitudinal associations with echocardiography. Am J Cardiol 2015,115(7)(Suppl.),59B-63B","journal-title":"Am J Cardiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cardfail.2013.01.010","volume":"19","author":"Wang Y.C.","year":"2013","unstructured":"Wang Y.C.; Yu C.C.; Chiu F.C.; Tsai C.T.; Lai L.P.; Hwang J.J.; Lin J.L.; Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail 2013,19(3),163-168","journal-title":"J Card Fail"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","volume":"50","author":"Januzzi J.L.","year":"2007","unstructured":"Januzzi J.L.; Peacock W.F.; Maisel A.S.; Chae C.U.; Jesse R.L.; Baggish A.L.; O\u2019Donoghue M.; Sakhuja R.; Chen A.A.; van Kimmenade R.R.; Lewandrowski K.B.; Lloyd-Jones D.M.; Wu A.H.; Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007,50(7),607-613","journal-title":"J Am Coll Cardiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/CIRCHEARTFAILURE.108.833707","volume":"2","author":"Shah R.V.","year":"2009","unstructured":"Shah R.V.; Chen-Tournoux A.A.; Picard M.H.; van Kimmenade R.R.; Januzzi J.L.; Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009,2(4),311-319","journal-title":"Circ Heart Fail"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1161\/CIRCHEARTFAILURE.113.001036","volume":"7","author":"Anand I.S.","year":"2014","unstructured":"Anand I.S.; Rector T.S.; Kuskowski M.; Snider J.; Cohn J.N.; Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail 2014,7(3),418-426","journal-title":"Circ Heart Fail"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"946","DOI":"10.5966\/sctm.2013-0055","volume":"2","author":"Corre J.","year":"2013","unstructured":"Corre J.; H\u00e9braud B.; Bourin P.; Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med 2013,2(12),946-952","journal-title":"Stem Cells Transl Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","volume":"50","author":"Kempf T.","year":"2007","unstructured":"Kempf T.; von Haehling S.; Peter T.; Allhoff T.; Cicoira M.; Doehner W.; Ponikowski P.; Filippatos G.S.; Rozentryt P.; Drexler H.; Anker S.D.; Wollert K.C.; Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007,50(11),1054-1060","journal-title":"J Am Coll Cardiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1093\/eurjhf\/hfs116","volume":"14","author":"Baessler A.","year":"2012","unstructured":"Baessler A.; Strack C.; Rousseva E.; Wagner F.; Bruxmeier J.; Schmiedel M.; Riegger G.; Lahmann C.; Loew T.; Schmitz G.; Fischer M.; Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 2012,14(11),1240-1248","journal-title":"Eur J Heart Fail"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ejhf.431","volume":"18","author":"Chan M.M.","year":"2016","unstructured":"Chan M.M.; Santhanakrishnan R.; Chong J.P.; Chen Z.; Tai B.C.; Liew O.W.; Ng T.P.; Ling L.H.; Sim D.; Leong K.T.G.; Yeo P.S.; Ong H.Y.; Jaufeerally F.; Wong R.C.; Chai P.; Low A.F.; Richards A.M.; Lam C.S.; Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2016,18(1),81-88","journal-title":"Eur J Heart Fail"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1177\/2047487317717065","volume":"24","author":"Pareek M.","year":"2017","unstructured":"Pareek M.; Bhatt D.L.; Vaduganathan M.; Biering-S\u00f8rensen T.; Qamar A.; Diederichsen A.C.; M\u00f8ller J.E.; Hindersson P.; Le\u00f3sd\u00f3ttir M.; Magnusson M.; Nilsson P.M.; Olsen M.H.; Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. Eur J Prev Cardiol 2017,24(15),1648-1659","journal-title":"Eur J Prev Cardiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e010107","DOI":"10.1161\/JAHA.118.010107","volume":"8","author":"Hijazi Z.","year":"2019","unstructured":"Hijazi Z.; Verdecchia P.; Oldgren J.; Andersson U.; Reboldi G.; Di Pasquale G.; Mazzotta G.; Angeli F.; Eikelboom J.W.; Ezekowitz M.D.; Connolly S.J.; Yusuf S.; Wallentin L.; Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to\u00a0Outcomes in Patients With Atrial Fibrillation: Experiences From the\u00a0RE - LY Trial. J Am Heart Assoc 2019,8(2),e010107","journal-title":"J Am Heart Assoc"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","volume":"76","author":"Barondes S.H.","year":"1994","unstructured":"Barondes S.H.; Castronovo V.; Cooper D.N.; Cummings R.D.; Drickamer K.; Feizi T.; Gitt M.A.; Hirabayashi J.; Hughes C.; Kasai K.; Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994,76(4),597-598","journal-title":"Cell"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/eurjhf\/hfs205","volume":"15","author":"Anand I.S.","year":"2013","unstructured":"Anand I.S.; Rector T.S.; Kuskowski M.; Adourian A.; Muntendam P.; Cohn J.N.; Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013,15(5),511-518","journal-title":"Eur J Heart Fail"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","volume":"110","author":"Sharma U.C.","year":"2004","unstructured":"Sharma U.C.; Pokharel S.; van Brakel T.J.; van Berlo J.H.; Cleutjens J.P.; Schroen B.; Andr\u00e9 S.; Crijns H.J.; Gabius H.J.; Maessen J.; Pinto Y.M.; Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004,110(19),3121-3128","journal-title":"Circulation"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","volume":"14","author":"Gehlken C.","year":"2018","unstructured":"Gehlken C.; Suthahar N.; Meijers W.C.; de Boer R.A.; Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 2018,14(1),75-92","journal-title":"Heart Fail Clin"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","volume":"6","author":"Yu L.","year":"2013","unstructured":"Yu L.; Ruifrok W.P.; Meissner M.; Bos E.M.; van Goor H.; Sanjabi B.; van der Harst P.; Pitt B.; Goldstein I.J.; Koerts J.A.; van Veldhuisen D.J.; Bank R.A.; van Gilst W.H.; Sillj\u00e9 H.H.; de Boer R.A.; Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013,6(1),107-117","journal-title":"Circ Heart Fail"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/07853890.2010.538080","volume":"43","author":"de Boer R.A.","year":"2011","unstructured":"de Boer R.A.; Lok D.J.; Jaarsma T.; van der Meer P.; Voors A.A.; Hillege H.L.; van Veldhuisen D.J.; Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011,43(1),60-68","journal-title":"Ann Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ahj.2014.02.011","volume":"167","author":"Meijers W.C.","year":"2014","unstructured":"Meijers W.C.; Januzzi J.L.; deFilippi C.; Adourian A.S.; Shah S.J.; van Veldhuisen D.J.; de Boer R.A.; Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J 2014,167(6),853-60.e4","journal-title":"Am Heart J"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","volume":"12","author":"Shah R.V.","year":"2010","unstructured":"Shah R.V.; Chen-Tournoux A.A.; Picard M.H.; van Kimmenade R.R.; Januzzi J.L.; Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010,12(8),826-832","journal-title":"Eur J Heart Fail"},{"key":"ref=71","first-page":"148","volume":"3","author":"Minami Y.","year":"2017","unstructured":"Minami Y.; Kajimoto K.; Sato N.; Hagiwara N.; Takano T.; C-reactive protein level on admission and time to and cause of death in patients hospitalized for acute heart failure. Eur Heart J Qual Care Clin Outcomes 2017,3(2),148-156","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1388-9842(02)00021-1","volume":"4","author":"Alonso-Mart\u00ednez J.L.","year":"2002","unstructured":"Alonso-Mart\u00ednez J.L.; Llorente-Diez B.; Echegaray-Agara M.; Olaz-Preciado F.; Urbieta-Echezarreta M.; Gonz\u00e1lez-Arencibia C.; C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002,4(3),331-336","journal-title":"Eur J Heart Fail"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/eurheartj\/ehl407","volume":"27","author":"Siiril\u00e4-Waris K.","year":"2006","unstructured":"Siiril\u00e4-Waris K.; Lassus J.; Melin J.; Peuhkurinen K.; Nieminen M.S.; Harjola V-P.; Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006,27(24),3011-3017","journal-title":"Eur Heart J"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s12471-017-1040-x","volume":"25","author":"van Boven N.","year":"2017","unstructured":"van Boven N.; Akkerhuis K.M.; Anroedh S.S.; Battes L.C.; Caliskan K.; Yassi W.; Manintveld O.C.; Cornel J.H.; Constantinescu A.A.; Boersma H.; Umans V.A.; Kardys I.; In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment. Neth Heart J 2017,25(11),634-642","journal-title":"Neth Heart J"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1161\/CIRCULATIONAHA.109.901413","volume":"121","author":"Blankenberg S.","year":"2010","unstructured":"Blankenberg S.; Zeller T.; Saarela O.; Havulinna A.S.; Kee F.; Tunstall-Pedoe H.; Kuulasmaa K.; Yarnell J.; Schnabel R.B.; Wild P.S.; CLINICAL PERSPECTIVE. Circulation 2010,121(22),2388-2397","journal-title":"Circulation"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","volume":"112","author":"Anand I.S.","year":"2005","unstructured":"Anand I.S.; Latini R.; Florea V.G.; Kuskowski M.A.; Rector T.; Masson S.; Signorini S.; Mocarelli P.; Hester A.; Glazer R.; Cohn J.N.; C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005,112(10),1428-1434","journal-title":"Circulation"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"Elliott P.","year":"2008","unstructured":"Elliott P.; Andersson B.; Arbustini E.; Bilinska Z.; Cecchi F.; Charron P.; Dubourg O.; K\u00fchl U.; Maisch B.; McKenna W.J.; Monserrat L.; Pankuweit S.; Rapezzi C.; Seferovic P.; Tavazzi L.; Keren A.; Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008,29(2),270-276","journal-title":"Eur Heart J"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/S0140-6736(57)91537-4","volume":"273","author":"Brigden W.","year":"1957","unstructured":"Brigden W.; Uncommon myocardial diseases: the non-coronary cardiomyopathies. Lancet 1957,273(7008),1243-1249","journal-title":"Lancet"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/hrt.2005.082271","volume":"93","author":"Jenni R.","year":"2007","unstructured":"Jenni R.; Oechslin E.N.; van der Loo B.; Isolated ventricular non-compaction of the myocardium in adults. Heart 2007,93(1),11-15","journal-title":"Heart"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1586\/14779072.2015.1053873","volume":"13","author":"Coats C.J.","year":"2015","unstructured":"Coats C.J.; Heywood W.E.; Mills K.; Elliott P.M.; Current applications of biomarkers in cardiomyopathies. Expert Rev Cardiovasc Ther 2015,13(7),825-837","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0735-1097(99)00172-2","volume":"34","author":"Mestroni L.","year":"1999","unstructured":"Mestroni L.; Rocco C.; Gregori D.; Sinagra G.; Di Lenarda A.; Miocic S.; Vatta M.; Pinamonti B.; Muntoni F.; Caforio A.L.; McKenna W.J.; Falaschi A.; Giacca M.; Camerini ; Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. J Am Coll Cardiol 1999,34(1),181-190","journal-title":"J Am Coll Cardiol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0960-8966(99)00018-8","volume":"9","author":"Hoogerwaard E.M.","year":"1999","unstructured":"Hoogerwaard E.M.; van der Wouw P.A.; Wilde A.A.; Bakker E.; Ippel P.F.; Oosterwijk J.C.; Majoor-Krakauer D.F.; van Essen A.J.; Leschot N.J.; de Visser M.; Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 1999,9(5),347-351","journal-title":"Neuromuscul Disord"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0022-510X(76)90165-9","volume":"29","author":"Somer H.","year":"1976","unstructured":"Somer H.; Dubowitz V.; Donner M.; Creatine kinase isoenzymes in neuromuscular diseases. J Neurol Sci 1976,29(2-4),129-136","journal-title":"J Neurol Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/hrt.2005.063818","volume":"93","author":"Linhart A.","year":"2007","unstructured":"Linhart A.; Elliott P.M.; The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007,93(4),528-535","journal-title":"Heart"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","volume":"108","author":"Weidemann F.","year":"2003","unstructured":"Weidemann F.; Breunig F.; Beer M.; Sandstede J.; Turschner O.; Voelker W.; Ertl G.; Knoll A.; Wanner C.; Strotmann J.M.; Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003,108(11),1299-1301","journal-title":"Circulation"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/eurheartj\/ehs397","volume":"34","author":"Rapezzi C.","year":"2013","unstructured":"Rapezzi C.; Arbustini E.; Caforio A.L.; Charron P.; Gimeno-Blanes J.; Heli\u00f6 T.; Linhart A.; Mogensen J.; Pinto Y.; Ristic A.; Seggewiss H.; Sinagra G.; Tavazzi L.; Elliott P.M.; Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013,34(19),1448-1458","journal-title":"Eur Heart J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"Mehta A.","year":"2004","unstructured":"Mehta A.; Ricci R.; Widmer U.; Dehout F.; Garcia de Lorenzo A.; Kampmann C.; Linhart A.; Sunder-Plassmann G.; Ries M.; Beck M.; Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004,34(3),236-242","journal-title":"Eur J Clin Invest"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/clc.21982","volume":"35","author":"Mantini N.","year":"2012","unstructured":"Mantini N.; Williams B.; Stewart J.; Rubinsztain L.; Kacharava A.; Cardiac sarcoid: a clinician\u2019s review on how to approach the patient with cardiac sarcoid. Clin Cardiol 2012,35(7),410-415","journal-title":"Clin Cardiol"},{"key":"ref=89","first-page":"A4815","volume":"61","author":"Fl\u00f8e A.","year":"2014","unstructured":"Fl\u00f8e A.; Hoffmann H.J.; Nissen P.H.; M\u00f8ller H.J.; Hilberg O.; Genotyping increases the yield of angiotensin-converting enzyme in sarcoidosis--a systematic review. Dan Med J 2014,61(5),A4815","journal-title":"Dan Med J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.111.050773","volume":"124","author":"Kremastinos D.T.","year":"2011","unstructured":"Kremastinos D.T.; Farmakis D.; Iron overload cardiomyopathy in clinical practice. Circulation 2011,124(20),2253-2263","journal-title":"Circulation"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1161\/CIRCULATIONAHA.109.907196","volume":"120","author":"Wood J.C.","year":"2009","unstructured":"Wood J.C.; History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 2009,120(20),1937-1939","journal-title":"Circulation"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"Falk R.H.","year":"2005","unstructured":"Falk R.H.; Diagnosis and management of the cardiac amyloidoses. Circulation 2005,112(13),2047-2060","journal-title":"Circulation"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cardfail.2008.10.030","volume":"15","author":"Ara\u00fajo J.P.","year":"2009","unstructured":"Ara\u00fajo J.P.; Louren\u00e7o P.; Azevedo A.; Fri\u00f5es F.; Rocha-Gon\u00e7alves F.; Ferreira A.; Bettencourt P.; Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail 2009,15(3),256-266","journal-title":"J Card Fail"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00395-009-0026-2","volume":"104","author":"Zimmermann O.","year":"2009","unstructured":"Zimmermann O.; Bienek-Ziolkowski M.; Wolf B.; Vetter M.; Baur R.; Mail\u00e4nder V.; Hombach V.; Torzewski J.; Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? Basic Res Cardiol 2009,104(5),591-599","journal-title":"Basic Res Cardiol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2636-2648, 2648a-2648d","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"Caforio A.L.","year":"2013","unstructured":"Caforio A.L.; Pankuweit S.; Arbustini E.; Basso C.; Gimeno-Blanes J.; Felix S.B.; Fu M.; Heli\u00f6 T.; Heymans S.; Jahns R.; Klingel K.; Linhart A.; Maisch B.; McKenna W.; Mogensen J.; Pinto Y.M.; Ristic A.; Schultheiss H.P.; Seggewiss H.; Tavazzi L.; Thiene G.; Yilmaz A.; Charron P.; Elliott P.M.; Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013,34(33),2636-2648, 2648a-2648d","journal-title":"Eur Heart J"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/S0735-1097(97)00317-3","volume":"30","author":"Lauer B.","year":"1997","unstructured":"Lauer B.; Niederau C.; K\u00fchl U.; Schannwell M.; Pauschinger M.; Strauer B-E.; Schultheiss H-P.; Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997,30(5),1354-1359","journal-title":"J Am Coll Cardiol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray J.J.","year":"2012","unstructured":"McMurray J.J.; Adamopoulos S.; Anker S.D.; Auricchio A.; B\u00f6hm M.; Dickstein K.; Falk V.; Filippatos G.; Fonseca C.; Gomez-Sanchez M.A.; Jaarsma T.; K\u00f8ber L.; Lip G.Y.; Maggioni A.P.; Parkhomenko A.; Pieske B.M.; Popescu B.A.; R\u00f8nnevik P.K.; Rutten F.H.; Schwitter J.; Seferovic P.; Stepinska J.; Trindade P.T.; Voors A.A.; Zannad F.; Zeiher A.; ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012,33(14),1787-1847","journal-title":"Eur Heart J"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/332078a0","volume":"332","author":"Sudoh T.","year":"1988","unstructured":"Sudoh T.; Kangawa K.; Minamino N.; Matsuo H.; A new natriuretic peptide in porcine brain. Nature 1988,332(6159),78-81","journal-title":"Nature"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.cardfail.2007.01.011","volume":"13","author":"Pieroni M.","year":"2007","unstructured":"Pieroni M.; Bellocci F.; Sanna T.; Verardo R.; Ierardi C.; Maseri A.; Frustaci A.; Crea F.; Increased brain natriuretic peptide secretion is a marker of disease progression in nonobstructive hypertrophic cardiomyopathy. J Card Fail 2007,13(5),380-388","journal-title":"J Card Fail"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","volume":"34","author":"Coats C.J.","year":"2013","unstructured":"Coats C.J.; Gallagher M.J.; Foley M.; O\u2019Mahony C.; Critoph C.; Gimeno J.; Dawnay A.; McKenna W.J.; Elliott P.M.; Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J 2013,34(32),2529-2537","journal-title":"Eur Heart J"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","volume":"61","author":"Geske J.B.","year":"2013","unstructured":"Geske J.B.; McKie P.M.; Ommen S.R.; Sorajja P.; B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. J Am Coll Cardiol 2013,61(24),2456-2460","journal-title":"J Am Coll Cardiol"},{"key":"ref=102","first-page":"107","author":"Falk R.H.","year":"2010","unstructured":"Falk R.H.; Dubrey S.W.;  Amyloid heart disease Amyloidosis 2010,107-128","journal-title":"Amyloid heart disease Amyloidosis"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"Elliott P.M.","year":"2014","unstructured":"Elliott P.M.; Anastasakis A.; Borger M.A.; Borggrefe M.; Cecchi F.; Charron P.; Hagege A.A.; Lafont A.; Limongelli G.; Mahrholdt H.; McKenna W.J.; Mogensen J.; Nihoyannopoulos P.; Nistri S.; Pieper P.G.; Pieske B.; Rapezzi C.; Rutten F.H.; Tillmanns C.; Watkins H.; 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014,35(39),2733-2779","journal-title":"Eur Heart J"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.amjcard.2012.08.055","volume":"111","author":"Coats C.J.","year":"2013","unstructured":"Coats C.J.; Parisi V.; Ramos M.; Janagarajan K.; O\u2019Mahony C.; Dawnay A.; Lachmann R.H.; Murphy E.; Mehta A.; Hughes D.; Elliott P.M.; Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. Am J Cardiol 2013,111(1),111-117","journal-title":"Am J Cardiol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.amjcard.2014.10.040","volume":"115","author":"Cheng H.","year":"2015","unstructured":"Cheng H.; Lu M.; Hou C.; Chen X.; Wang J.; Yin G.; Chu J.; Zhang S.; Prasad S.K.; Pu J.; Zhao S.; Relation between N-terminal pro-brain natriuretic peptide and cardiac remodeling and function assessed by cardiovascular magnetic resonance imaging in patients with arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol 2015,115(3),341-347","journal-title":"Am J Cardiol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jacc.2013.03.055","volume":"62","author":"Kubo T.","year":"2013","unstructured":"Kubo T.; Kitaoka H.; Yamanaka S.; Hirota T.; Baba Y.; Hayashi K.; Iiyama T.; Kumagai N.; Tanioka K.; Yamasaki N.; Matsumura Y.; Furuno T.; Sugiura T.; Doi Y.L.; Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. J Am Coll Cardiol 2013,62(14),1252-1259","journal-title":"J Am Coll Cardiol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s00380-006-0909-1","volume":"21","author":"Taniguchi R.","year":"2006","unstructured":"Taniguchi R.; Sato Y.; Nishio Y.; Kimura T.; Kita T.; Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels 2006,21(6),344-349","journal-title":"Heart Vessels"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jjcc.2011.11.008","volume":"59","author":"Kitaoka H.","year":"2012","unstructured":"Kitaoka H.; Kubo T.; Baba Y.; Yamasaki N.; Matsumura Y.; Furuno T.; Doi Y.L.; Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J Cardiol 2012,59(2),209-214","journal-title":"J Cardiol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCHEARTFAILURE.107.746172","volume":"1","author":"Rosenberg M.","year":"2008","unstructured":"Rosenberg M.; Zugck C.; Nelles M.; Juenger C.; Frank D.; Remppis A.; Giannitsis E.; Katus H.A.; Frey N.; Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008,1(1),43-49","journal-title":"Circ Heart Fail"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3109\/13506129.2014.940457","volume":"21","author":"Kristen A.V.","year":"2014","unstructured":"Kristen A.V.; Rosenberg M.; Lindenmaier D.; Merkle C.; Steen H.; Andre F.; Sch\u00f6nland S.O.; Schnabel P.A.; Schuster T.; R\u00f6cken C.; Giannitsis E.; Katus H.A.; Frey N.; Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid 2014,21(3),202-210","journal-title":"Amyloid"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"A763","DOI":"10.1016\/S0735-1097(18)31304-4","volume":"71","author":"Yamamoto M.","year":"2018","unstructured":"Yamamoto M.; Hanatani S.; Toshifumi I.; Satoru Y.; Kyoko H.; Takashio S.; Izumiya Y.; Tsujita K.; Human epididymis protein 4 is a novel fibrosis marker to predict pathological cardiac remodeling and adverse outcomes in patients with dilated cardiomyopathy. J Am Coll Cardiol 2018,71(11),A763","journal-title":"J Am Coll Cardiol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/hrt.2006.095810","volume":"93","author":"de la Porte P.W.","year":"2007","unstructured":"de la Porte P.W.; Lok D.J.; van Veldhuisen D.J.; van Wijngaarden J.; Cornel J.H.; Zuithoff N.P.; Badings E.; Hoes A.W.; Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study. Heart 2007,93(7),819-825","journal-title":"Heart"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cardfail.2008.02.014","volume":"14","author":"Radauceanu A.","year":"2008","unstructured":"Radauceanu A.; Ducki C.; Virion J-M.; Rossignol P.; Mallat Z.; McMurray J.; Van Veldhuisen D.J.; Tavazzi L.; Mann D.L.; Capiaumont-Vin J.; Li M.; Hanriot D.; Zannad F.; Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008,14(6),467-474","journal-title":"J Card Fail"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1023\/B:GLYC.0000014082.99675.2f","volume":"19","author":"Ochieng J.","year":"2002","unstructured":"Ochieng J.; Furtak V.; Lukyanov P.; Extracellular functions of galectin-3. Glycoconj J 2002,19(7-9),527-535","journal-title":"Glycoconj J"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","volume":"296","author":"Liu Y-H.","year":"2009","unstructured":"Liu Y-H.; D\u2019Ambrosio M.; Liao T-D.; Peng H.; Rhaleb N-E.; Sharma U.; Andr\u00e9 S.; Gabius H-J.; Carretero O.A.; N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009,296(2),H404-H412","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00392-012-0500-y","volume":"102","author":"Lok D.J.","year":"2013","unstructured":"Lok D.J.; Lok S.I.; Bruggink-Andr\u00e9 de la Porte P.W.; Badings E.; Lipsic E.; van Wijngaarden J.; de Boer R.A.; van Veldhuisen D.J.; van der Meer P.; Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2013,102(2),103-110","journal-title":"Clin Res Cardiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/BF03347297","volume":"21","author":"Clerico A.","year":"1998","unstructured":"Clerico A.; Iervasi G.; Del Chicca M.G.; Emdin M.; Maffei S.; Nannipieri M.; Sabatino L.; Forini F.; Manfredi C.; Donato L.; Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998,21(3),170-179","journal-title":"J Endocrinol Invest"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1084\/jem.20171274","volume":"215","author":"Hulsmans M.","year":"2018","unstructured":"Hulsmans M.; Sager H.B.; Roh J.D.; Valero-Mu\u00f1oz M.; Houstis N.E.; Iwamoto Y.; Sun Y.; Wilson R.M.; Wojtkiewicz G.; Tricot B.; Osborne M.T.; Hung J.; Vinegoni C.; Naxerova K.; Sosnovik D.E.; Zile M.R.; Bradshaw A.D.; Liao R.; Tawakol A.; Weissleder R.; Rosenzweig A.; Swirski F.K.; Sam F.; Nahrendorf M.; Cardiac macrophages promote diastolic dysfunction. J Exp Med 2018,215(2),423-440","journal-title":"J Exp Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1161\/CIRCRESAHA.109.213157","volume":"106","author":"Baldeviano G.C.","year":"2010","unstructured":"Baldeviano G.C.; Barin J.G.; Talor M.V.; Srinivasan S.; Bedja D.; Zheng D.; Gabrielson K.; Iwakura Y.; Rose N.R.; Cihakova D.; Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010,106(10),1646-1655","journal-title":"Circ Res"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1161\/CIRCRESAHA.115.303567","volume":"115","author":"Heidt T.","year":"2014","unstructured":"Heidt T.; Courties G.; Dutta P.; Sager H.B.; Sebas M.; Iwamoto Y.; Sun Y.; Da Silva N.; Panizzi P.; van der Laan A.M.; Swirski F.K.; Weissleder R.; Nahrendorf M.; Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ Res 2014,115(2),284-295","journal-title":"Circ Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"E2676","DOI":"10.3390\/ijms19092676","volume":"19","author":"Larsen K.M.","year":"2018","unstructured":"Larsen K.M.; Minaya M.K.; Vaish V.; Pe\u00f1a M.M.O.; The Role of IL-33\/ST2 Pathway in Tumorigenesis. Int J Mol Sci 2018,19(9),E2676","journal-title":"Int J Mol Sci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1161\/HYPERTENSIONAHA.118.11157","volume":"72","author":"Ghali R.","year":"2018","unstructured":"Ghali R.; Altara R.; Louch W.E.; Cataliotti A.; Mallat Z.; Kaplan A.; Zouein F.A.; Booz G.W.; IL-33 (Interleukin 33)\/sST2 (Soluble Suppression of Tumorigenicity 2) axis in hypertension and heart failure. Hypertension 2018,72(4),818-828","journal-title":"Hypertension"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12265-017-9775-8","volume":"11","author":"Tseng C.C.S.","year":"2018","unstructured":"Tseng C.C.S.; Huibers M.M.H.; van Kuik J.; de Weger R.A.; Vink A.; de Jonge N.; The interleukin-33\/ST2 pathway is expressed in the failing human heart and associated with pro-fibrotic remodeling of the myocardium. J Cardiovasc Transl Res 2018,11(1),15-21","journal-title":"J Cardiovasc Transl Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.2354","volume":"17","author":"Kempf T.","year":"2011","unstructured":"Kempf T.; Zarbock A.; Widera C.; Butz S.; Stadtmann A.; Rossaint J.; Bolomini-Vittori M.; Korf-Klingebiel M.; Napp L.C.; Hansen B.; Kanwischer A.; Bavendiek U.; Beutel G.; Hapke M.; Sauer M.G.; Laudanna C.; Hogg N.; Vestweber D.; Wollert K.C.; GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011,17(5),581-588","journal-title":"Nat Med"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"490842","DOI":"10.1155\/2015\/490842","volume":"2015","author":"Adela R.","year":"2015","unstructured":"Adela R.; Banerjee S.K.; GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective. J Diabetes Res 2015,2015,490842","journal-title":"J Diabetes Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/eurjhf\/hfs120","volume":"14","author":"Lok S.I.","year":"2012","unstructured":"Lok S.I.; Winkens B.; Goldschmeding R.; van Geffen A.J.; Nous F.M.; van Kuik J.; van der Weide P.; Kl\u00f6pping C.; Kirkels J.H.; Lahpor J.R.; Doevendans P.A.; de Jonge N.; de Weger R.A.; Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012,14(11),1249-1256","journal-title":"Eur J Heart Fail"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ejhf.495","volume":"18","author":"Vegter E.L.","year":"2016","unstructured":"Vegter E.L.; van der Meer P.; de Windt L.J.; Pinto Y.M.; Voors A.A.; MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail 2016,18(5),457-468","journal-title":"Eur J Heart Fail"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/ejhf.801","volume":"19","author":"Devaux Y.","year":"2017","unstructured":"Devaux Y.; Creemers E.E.; Boon R.A.; Werfel S.; Thum T.; Engelhardt S.; Dimmeler S.; Squire I.; Network C.; Circular RNAs in heart failure. Eur J Heart Fail 2017,19(6),701-709","journal-title":"Eur J Heart Fail"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ejhf.244","volume":"17","author":"Watson C.J.","year":"2015","unstructured":"Watson C.J.; Gupta S.K.; O\u2019Connell E.; Thum S.; Glezeva N.; Fendrich J.; Gallagher J.; Ledwidge M.; Grote-Levi L.; McDonald K.; Thum T.; MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 2015,17(4),405-415","journal-title":"Eur J Heart Fail"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/eurjhf\/hft018","volume":"15","author":"Dickinson B.A.","year":"2013","unstructured":"Dickinson B.A.; Semus H.M.; Montgomery R.L.; Stack C.; Latimer P.A.; Lewton S.M.; Lynch J.M.; Hullinger T.G.; Seto A.G.; van Rooij E.; Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 2013,15(6),650-659","journal-title":"Eur J Heart Fail"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ejhf.961","volume":"20","author":"Masson S.","year":"2018","unstructured":"Masson S.; Batkai S.; Beermann J.; B\u00e4r C.; Pfanne A.; Thum S.; Magnoli M.; Balconi G.; Nicolosi G.L.; Tavazzi L.; Latini R.; Thum T.; Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Fail 2018,20(1),78-85","journal-title":"Eur J Heart Fail"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"Zhu N.","year":"2020","unstructured":"Zhu N.; Zhang D.; Wang W.; Li X.; Yang B.; Song J.; Zhao X.; Huang B.; Shi W.; Lu R.; Niu P.; Zhan F.; Ma X.; Wang D.; Xu W.; Wu G.; Gao G.F.; Tan W.; A novel coronavirus from patients with pneumonia in China. N Engl J Med 2020,382(8),727-733","journal-title":"N Engl J Med"},{"key":"ref=133","first-page":"rs.3.rs-34729.","author":"Dawson D.","year":"2020","unstructured":"Dawson D.; Dominic P.; Sheth A.; Modi M.; Prognostic value of Cardiac Biomarkers in COVID-19 Infection: A Meta-analysis. Res Sq 2020,rs.3.rs-34729.","journal-title":"Res Sq"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"Yang X.","year":"2020","unstructured":"Yang X.; Yu Y.; Xu J.; Shu H.; Xia J.; Liu H.; Wu Y.; Zhang L.; Yu Z.; Fang M.; Yu T.; Wang Y.; Pan S.; Zou X.; Yuan S.; Shang Y.; Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020,8(5),475-481","journal-title":"Lancet Respir Med"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1161\/CIRCULATIONAHA.120.047164","volume":"141","author":"Fried J.A.","year":"2020","unstructured":"Fried J.A.; Ramasubbu K.; Bhatt R.; Topkara V.K.; Clerkin K.J.; Horn E.; Rabbani L.; Brodie D.; Jain S.S.; Kirtane A.J.; Masoumi A.; Takeda K.; Kumaraiah D.; Burkhoff D.; Leon M.; Schwartz A.; Uriel N.; Sayer G.; The Variety of Cardiovascular Presentations of COVID-19. Circulation 2020,141(23),1930-1936","journal-title":"Circulation"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.cpcardiol.2020.100648","volume":"45","author":"Ahmed S.I.","year":"2020","unstructured":"Ahmed S.I.; Khan S.; Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients. Curr Probl Cardiol 2020,45(9),100648","journal-title":"Curr Probl Cardiol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/eurheartj\/ehaa286","volume":"41","author":"Sala S.","year":"2020","unstructured":"Sala S.; Peretto G.; Gramegna M.; Palmisano A.; Villatore A.; Vignale D.; De Cobelli F.; Tresoldi M.; Cappelletti A.M.; Basso C.; Godino C.; Esposito A.; Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J 2020,41(19),1861-1862","journal-title":"Eur Heart J"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"109894","DOI":"10.1016\/j.jclinane.2020.109894","volume":"65","author":"Su M.","year":"2020","unstructured":"Su M.; Wang Y.; Peng J.; Wu M.J.; Deng W.; Yang Y.S.; Elevated cardiac biomarkers are associated with increased mortality for inpatients with COVID-19: A retrospective case-control study. J Clin Anesth 2020,65,109894","journal-title":"J Clin Anesth"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2459\/JCM.0b013e328361d1ef","volume":"14","author":"Sherwi N.","year":"2013","unstructured":"Sherwi N.; Pellicori P.; Joseph A.C.; Buga L.; Old and newer biomarkers in heart failure: from pathophysiology to clinical significance. J Cardiovasc Med (Hagerstown) 2013,14(10),690-697","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2217\/bmm.14.31","volume":"8","author":"Jungbauer C.G.","year":"2014","unstructured":"Jungbauer C.G.; Riedlinger J.; Block D.; Stadler S.; Birner C.; Buesing M.; K\u00f6nig W.; Riegger G.; Maier L.; Luchner A.; Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure. Biomarkers Med 2014,8(6),777-789","journal-title":"Biomarkers Med"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.109.929661","volume":"122","author":"Velagaleti R.S.","year":"2010","unstructured":"Velagaleti R.S.; Gona P.; Larson M.G.; Wang T.J.; Levy D.; Benjamin E.J.; Selhub J.; Jacques P.F.; Meigs J.B.; Tofler G.H.; Vasan R.S.; Multimarker approach for the prediction of heart failure incidence in the community. Circulation 2010,122(17),1700-1706","journal-title":"Circulation"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","volume":"126","author":"Wang T.J.","year":"2012","unstructured":"Wang T.J.; Wollert K.C.; Larson M.G.; Coglianese E.; McCabe E.L.; Cheng S.; Ho J.E.; Fradley M.G.; Ghorbani A.; Xanthakis V.; Kempf T.; Benjamin E.J.; Levy D.; Vasan R.S.; Januzzi J.L.; Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012,126(13),1596-1604","journal-title":"Circulation"},{"key":"ref=143","author":"Zipes D.P.","year":"2018","unstructured":"Zipes D.P.; Libby P.; Bonow R.O.; Mann D.L.; Tomaselli G.F.;  Braunwald\u2019s Heart Disease E-Book: A Textbook of Cardiovascular Medicine 2018","journal-title":"Braunwald\u2019s Heart Disease E-Book: A Textbook of Cardiovascular Medicine"},{"key":"ref=144","author":"Mann D.L.","year":"2014","unstructured":"Mann D.L.; Zipes D.P.; Libby P.; Bonow R.O.;  Braunwald\u2019s Heart Disease E-Book: A Textbook of Cardiovascular Medicine 2014","journal-title":"Braunwald\u2019s Heart Disease E-Book: A Textbook of Cardiovascular Medicine"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530320999200831171748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185443\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530320999200831171748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T02:03:13Z","timestamp":1657159393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185443\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530320999200831171748","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}